Seguridad y efectividad de la estimulación del área de la rama del paquete izquierda versus la terapia de resincronización cardíaca convencional en la insuficiencia cardíaca (SYNCHRONICITY)
This study will compare two different methods to pace the heart to treat heart failure including:
- The current standard method of implanting a pacing lead in a vein on the surface of the left lower chamber of the heart (left ventricle) to deliver heart failure therapy. This method is called Cardiac Resynchronization Therapy (CRT).
- The other method is using a lead implanted in the Left Bundle Branch Area (LBBA) of your heart. This method is called Left Bundle Branch Area Pacing or LBBAP. This lead is approved by the Food and Drug Administration (FDA) to be implanted in this area of the heart, but not to provide heart failure treatment.
Descripción general del estudio
Estado
Estado
Condiciones
Condiciones
Intervención / Tratamiento
Intervención / Tratamiento
Tipo de estudio
Tipo de estudio
Inscripción (Estimado)
Inscripción
Fase
Fase
- No aplica
Contactos y Ubicaciones
Estudio Contacto
Estudio Contacto
- Nombre: Jacqueline Beaulieu
- Número de teléfono: 1-800-227-3422
- Correo electrónico: jacqueline.beaulieu@bsci.com
Ubicaciones de estudio
-
-
Alabama
-
Huntsville, Alabama, Estados Unidos, 35801
- Reclutamiento
- Heart Center Research, LLC
-
Contacto:
- John Jennings, Dr.
-
Investigador principal:
- John Jennings, Dr.
-
Mobile, Alabama, Estados Unidos, 36608
- Reclutamiento
- Mobile Infirmary Medical Center
-
Contacto:
- Ernest Matthew Quin, Dr.
-
Investigador principal:
- Ernest Matthew Quin, Dr.
-
-
Arizona
-
Phoenix, Arizona, Estados Unidos, 85054
- Reclutamiento
- Mayo Clinic Phoenix
-
Contacto:
- Mayank Sardana, MD
-
Investigador principal:
- Mayank Sardana, MD
-
-
Arkansas
-
Jonesboro, Arkansas, Estados Unidos, 72401
- Reclutamiento
- Arrhythmia Research Group
-
Contacto:
- Devi Nair, Dr.
-
Investigador principal:
- Devi Nair, Dr.
-
-
California
-
La Jolla, California, Estados Unidos, 92037
- Reclutamiento
- Scripps Memorial Hospital
-
Contacto:
- Nicolas Olson, MD
-
Investigador principal:
- Nicolas Olson, MD
-
Los Angeles, California, Estados Unidos, 90048
- Reclutamiento
- Cedars Sinai Medical Center
-
Investigador principal:
- Ashkan Ehdaie, MD
-
Contacto:
- Ashkan Ehdaie, MD
-
Oakland, California, Estados Unidos, 94609
- Reclutamiento
- Alta Bates Summit Medical Center
-
Contacto:
- Rajan Shah, Dr.
-
Investigador principal:
- Rajan Shah, Dr.
-
Santa Monica, California, Estados Unidos, 90404
- Reclutamiento
- Pacific Heart Institute
-
Contacto:
- Stephen Tang, MD
-
Investigador principal:
- Stephan Tang, MD
-
Torrance, California, Estados Unidos, 90505
- Reclutamiento
- Torrance Medical Center
-
Investigador principal:
- Gene Kim, MD
-
Contacto:
- Gene Kim, MD
-
Ventura, California, Estados Unidos, 93003
- Reclutamiento
- Cardiology Associates Medical Group, Inc.
-
Contacto:
- Jonathan Dukes, Dr.
-
Investigador principal:
- Jonathan Dukes, Dr.
-
-
District of Columbia
-
Washington D.C., District of Columbia, Estados Unidos, 20010
- Reclutamiento
- Washington Hospital Center
-
Contacto:
- Cyrus Hadadi, MD
-
Investigador principal:
- Cyrus Hadadi, MD
-
-
Florida
-
Sarasota, Florida, Estados Unidos, 34239
- Reclutamiento
- Sarasota Memorial Hospital
-
Contacto:
- Antonio Moretta, Dr.
-
Investigador principal:
- Antonio Moretta, Dr.
-
Tampa, Florida, Estados Unidos, 33613
- Reclutamiento
- AdventHealth Tampa
-
Investigador principal:
- Kenneth Yamamura, MD
-
Contacto:
- Kenneth Yamamura, MD
-
-
Georgia
-
Atlanta, Georgia, Estados Unidos, 30309
- Reclutamiento
- Piedmont Hospital
-
Contacto:
- Kavita Krishnasamy, MD
-
Investigador principal:
- Kavita Krishnasamy, MD
-
Atlanta, Georgia, Estados Unidos, 30322
- Reclutamiento
- Emory University Hospital
-
Contacto:
- Anand Shah, MD
-
Investigador principal:
- Anand Shah, MD
-
-
Idaho
-
Meridian, Idaho, Estados Unidos, 83642
- Reclutamiento
- St. Luke's Idaho Cardiology Associates
-
Contacto:
- Justice Oranefo, MD
-
Investigador principal:
- Justice Oranefo, MD
-
-
Illinois
-
Hinsdale, Illinois, Estados Unidos, 60521
- Reclutamiento
- University of Chicago
-
Contacto:
- Shrinath Yeshwant, MD
-
Investigador principal:
- Shrinath Yeshwant, MD
-
Naperville, Illinois, Estados Unidos, 60540
- Retirado
- Midwest Cardiovascular Institute
-
-
Indiana
-
Indianapolis, Indiana, Estados Unidos, 46250
- Reclutamiento
- Community Heart and Vascular Hospital
-
Contacto:
- Krishna Malineni, MD
-
Investigador principal:
- Krishna Malineni, MD
-
-
Iowa
-
Iowa City, Iowa, Estados Unidos, 52242
- Reclutamiento
- University of Iowa Hospitals and Clinics
-
Investigador principal:
- Paari Dominic, MD
-
Contacto:
- Paari Dominic, MD
-
-
Kentucky
-
Louisville, Kentucky, Estados Unidos, 40207
- Reclutamiento
- Baptist Hospital East Louisville
-
Investigador principal:
- Kevin Parrott, MD
-
Contacto:
- Kevin Parrott, MD
-
-
Massachusetts
-
Fall River, Massachusetts, Estados Unidos, 02720
- Reclutamiento
- Southcoast Physicians Group
-
Contacto:
- Arnoldas Giedrimas, MD
-
Investigador principal:
- Arnoldas Giedrimas, MD
-
-
Michigan
-
Ann Arbor, Michigan, Estados Unidos, 48109
- Reclutamiento
- University of Michigan Hospitals
-
Investigador principal:
- Thomas Crawford, MD
-
Contacto:
- Thomas Crawford, MD
-
Grand Rapids, Michigan, Estados Unidos, 49525
- Reclutamiento
- Corewell Health
-
Contacto:
- Jawad Wassim, MD
-
Investigador principal:
- Jawad Wassim, MD
-
-
Minnesota
-
Duluth, Minnesota, Estados Unidos, 55805
- Retirado
- St. Mary's Duluth Clinic Regional Heart Center
-
Saint Cloud, Minnesota, Estados Unidos, 56303
- Retirado
- Centracare Heart and Vascular Center
-
-
New Jersey
-
Morristown, New Jersey, Estados Unidos, 07932
- Reclutamiento
- Morristown Medical Center
-
Contacto:
- Michael Katz, MD
-
Investigador principal:
- Michael Katz, MD
-
-
New York
-
Albany, New York, Estados Unidos, 12211
- Reclutamiento
- Capital Cardiology Associates
-
Contacto:
- Rizwan Alimohammad, MD
-
Investigador principal:
- Rizwan Alimohammad, MD
-
Flushing, New York, Estados Unidos, 11355
- Reclutamiento
- New York Hospital Queens
-
Contacto:
- Seth Goldbarg, Dr.
-
Investigador principal:
- Seth Goldbarg, Dr.
-
New York, New York, Estados Unidos, 10021
- Reclutamiento
- Weill Cornell Medical University
-
Contacto:
- Jim Cheung, Dr.
-
Investigador principal:
- Jim Cheung, Dr.
-
New York, New York, Estados Unidos, 14621
- Reclutamiento
- Rochester General Hospital
-
Contacto:
- Dmitry Chuprun, MD
-
Investigador principal:
- Dmitry Chuprun, MD
-
Syracuse, New York, Estados Unidos, 13057
- Reclutamiento
- SUNY-Upstate Medical University
-
Contacto:
- Jorge Romero, MD
-
Investigador principal:
- Jorge Romero, MD
-
-
North Carolina
-
Charlotte, North Carolina, Estados Unidos, 28204
- Reclutamiento
- Sanger Heart and Vascular Institute
-
Contacto:
- Navid Nafissi, MD
-
Investigador principal:
- Navid Nafissi, MD
-
Durham, North Carolina, Estados Unidos, 27710
- Reclutamiento
- Duke University Medical Center
-
Contacto:
- Daniel Friedman, MD
-
Investigador principal:
- Daniel Friedman, MD
-
-
Ohio
-
Columbus, Ohio, Estados Unidos, 43219
- Reclutamiento
- Mount Carmel Health System
-
Contacto:
- Kamel Addo, MD
-
Investigador principal:
- Kamel Addo, MD
-
Columbus, Ohio, Estados Unidos, 43214
- Reclutamiento
- OhioHealth Research and Innovation Institute-Riverside Methodist Hospital
-
Contacto:
- Anish Amin, MD
-
Investigador principal:
- Anish Amin, MD
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Estados Unidos, 19104
- Reclutamiento
- Penn Presbyterian Medical Center
-
Contacto:
- John Bullinga, MD
-
Investigador principal:
- John Bullinga, MD
-
Wilkes-Barre, Pennsylvania, Estados Unidos, 18702
- Reclutamiento
- Geisinger Wyoming Valley
-
Investigador principal:
- Pugazhendhi Vijayaraman, MD
-
Contacto:
- Pugazhendhi Vijayaraman, MD
-
-
South Dakota
-
Sioux Falls, South Dakota, Estados Unidos, 57108
- Reclutamiento
- Avera Heart Hospital of South Dakota
-
Contacto:
- Christopher Stanton, Dr.
-
Investigador principal:
- Christopher Stanton, Dr.
-
-
Tennessee
-
Nashville, Tennessee, Estados Unidos, 37205
- Reclutamiento
- St.Thomas Health
-
Contacto:
- Ricardo Lugo, MD
-
Investigador principal:
- Ricardo Lugo, MD
-
-
Texas
-
Plano, Texas, Estados Unidos, 75093
- Reclutamiento
- Heart Hospital Baylor Plano
-
Contacto:
- Mustafa Dohadwala, MD
-
Investigador principal:
- Mustafa Dohadwala, MD
-
Tyler, Texas, Estados Unidos, 75701
- Reclutamiento
- Christus Trinity Mother Frances Health System
-
Contacto:
- Stanislov Weiner, Dr.
-
Investigador principal:
- Stanislov Weiner, Dr.
-
-
Virginia
-
Charlottesville, Virginia, Estados Unidos, 22908
- Reclutamiento
- University of Virginia Medical Center
-
Investigador principal:
- Pamela Mason, MD
-
Contacto:
- Pamela Mason, MD
-
-
Criterios de participación
Criterio de elegibilidad
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
-
Patient is age 18 years or above, or of legal age to give informed consent specific to state and national law
-
Patient meets a guideline-based indication for a de novo CRT-D device
-
Primary prevention indication for ICD therapy
-
Ischemic or nonischemic cardiomyopathy with LVEF ≤ 35% within 6 months of enrollment (LVEF must be assessed after the subject has been on GDMT for a minimum of 3 months) using an appropriate method of assessment (i.e. Echo, MRI, etc)
-
NYHA class II-IV despite maximally tolerated guideline directed medical therapy (GDMT)* for at least 3 months
*GDMT is defined as all four drug classes listed below for at least 3 months prior to enrollment unless the investigator provides justification (e.g., contraindicated, not tolerated or cost): Renin Angiotensin System Inhibitors (ACE, ARB, or ARNI) Evidence based betablockers (metoprolol succinate, carvedilol, bisoprolol) Mineralocorticoid antagonists SGLT2 Inhibitor medications
-
Sinus rhythm with left bundle branch block (LBBB) defined as a QRS ≥ 140 ms in men and ≥ 130 ms in women with a predominantly negative deflection (QS or rS in lead V1 and mid QRS notching or slurring in at least two of the following leads: 1, aVL, V1, V2, V5, V6) within 3 months of enrollment
-
Patient is willing to participate in LATITUDE™ NXT remote patient monitoring
-
Patient is willing and capable of providing informed consent and participating in all testing associated with this investigation at an approved study site and at the protocol defined intervals (Note: Use of a legally authorized representative (LAR) is not allowed)
-
Patient plans to remain geographically stable (not permanently moving to another location) and can commit to all study participation requirements (procedure, follow-up visits and testing requirements)
Exclusion Criteria:
- Persistent or permanent atrial fibrillation (AF) within 3 months prior to enrollment and documented in the medical record
- Frequent premature ventricular contractions (PVCs), atrial arrhythmias, and/or other causes of expected percentage of cardiac physiologic pacing (CPP) delivery below 95% at the time of enrollment
- Non-LBBB conduction abnormalities (including right bundle branch block (RBB) or intraventricular conduction delay (IVCD)) within 3 months prior to enrollment
- Complete, second degree or high degree atrioventricular (AV) block, that requires pacing at the time of enrollment
- Current or prior pacemaker, ICD or CRT implant (Also includes non-transvenous ICD technology and leadless pacemakers)
- Prior or planned mechanical or bioprosthetic tricuspid valve replacement
- Currently receiving or previously received positive inotrope therapy within 3 months prior to enrollment
- Unstable angina, acute myocardial infarction, coronary artery bypass grafting, or percutaneous coronary intervention within 3 months prior to enrollment
- History of heart transplantation or left ventricular assist device (LVAD) implantation
- Less than 1 year of life expectancy at the time of enrollment
- Anticipated heart transplantation or LVAD implantation within 1 year of enrollment
- History of ventricular septal defect (VSD)
- Complex congenital heart disease
- Documented diagnosis of cardiac amyloidosis
- Known occlusion or other reason limiting central venous access for transvenous leads
- Women of childbearing potential who are, or plan to become, pregnant during the course of the study (assessment per investigator's discretion)
- Patient currently requiring dialysis
- Patient with known or suspected sensitivity to Dexamethasone Acetate (DXA)
- Patient with contrast dye allergy or unwilling/able to undergo pre-treatment with steroids and/or diphenhydramine
- Inability or refusal to comply with the follow-up schedule including subject living at such a distance from the investigational site that attending follow-up visits would be unusually difficult or burdensome
- Patient is enrolled in any other concurrent study. Co-enrollment into other studies such as observational studies/registries needs prior written approval by BSC. Local mandatory governmental registries are accepted for co-enrollment without approval by BSC.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Único
Número de brazos
Armas e Intervenciones
Grupo de participantes/brazoGrupo de participantes/brazo |
Intervención / TratamientoIntervención / Tratamiento |
|---|---|
|
Comparador activo: CRT Cohort
Participants will be randomized, implanted with a BSC CRT-D device using a Quadripolar lead, and device programmed to the respective cohort. |
Participants randomized to this cohort will receive a BSC system: CRT-D, Right Atrial Lead (RA), Defibrillation Lead (RV), Quadripolar LV Lead. |
|
Experimental: LBBA Cohort
Participants will be randomized, implanted with a BSC CRT-D using the INGEVITY+ pace/sense lead implanted in the LBBA, and device programmed to the respective cohort. |
Participants randomized to this cohort will receive a BSC system: CRT-D, Right Atrial Lead (RA), Defibrillation Lead (RV), INGEVITY+ pace/sense Lead (implanted in the LBBA) |
¿Qué mide el estudio?
Medidas de resultado primarias
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Composite of reduction in all-cause mortality, heart transplant, left ventricular assist device, heart failure events, ventricular tachycardia/ventricular fibrillation requiring device therapy or external defibrillation/cardioversion.
Periodo de tiempo: Through study completion, up to maximum of 5 years
|
The primary effectiveness endpoint is a composite of reduction in all-cause mortality, heart transplant, left ventricular assist device (LVAD), time to first heart failure (HF) events, time to first ventricular tachycardia (VT) / ventricular fibrillation (VF) requiring device therapy or external defibrillation/cardioversion. |
Through study completion, up to maximum of 5 years
|
|
System-related complication-free rate
Periodo de tiempo: 12 months
|
The primary safety endpoint is System-related complication-free rate of LBBAP at 12 months. This will be a single-arm analysis of the LBBAP group compared to a performance goal |
12 months
|
Medidas de resultado secundarias
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Win ratio composite assessment
Periodo de tiempo: Through study completion, up to a maximum of 5 years
|
Win Ratio Ranking: 1) Death 2) Heart Transplant/LVAD 3) Number of Heart Failure (HF) events (includes in-patient, out-patient and HF re-admission 4) Number of VT/VF episodes requiring device therapy or external defibrillation/cardioversion (one episode per 24 hours 5) Change in MLHFQ (Minnesota Living with Heart Failure Questionnaire) quality of life |
Through study completion, up to a maximum of 5 years
|
|
Composite of reduction in all-cause mortality, heart transplant, left ventricular assist device, heart failure events, ventricular tachycardia/ ventricular fibrillation requiring device therapy or external defibrillation/cardioversion.
Periodo de tiempo: Through study completion, up to a maximum of 5 years
|
The primary effectiveness endpoint is a composite of reduction in all-cause mortality, heart transplant, left ventricular assist device (LVAD), time to first heart failure (HF) events, time to first ventricular tachycardia (VT) / ventricular fibrillation (VF) requiring device therapy or external defibrillation/cardioversion. |
Through study completion, up to a maximum of 5 years
|
|
System-related complication-free rate between randomized arms
Periodo de tiempo: 12 months
|
System-related complication-free rate of LBBAP at 12 months. This will compare the two randomized arms. |
12 months
|
Colaboradores e Investigadores
Patrocinador
Patrocinador
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Inicio del estudio
Finalización primaria (Estimado)
Finalización primaria
Finalización del estudio (Estimado)
Finalización del estudio
Fechas de registro del estudio
Enviado por primera vez
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Publicado por primera vez
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización publicada
Última actualización enviada que cumplió con los criterios de control de calidad
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
Otros números de identificación del estudio
- C2403
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .